The MeCo Score™ is the first and only clinically validated predictive biomarker test to help with therapy selection for patients with early-stage breast cancer who have a higher risk of relapse (1,2,3) yet may benefit from an FDA-approved antifibrotic therapy (3)*.
[1] Watson, A.W. et al. (2021). Cell Reports. 29;35(13):109293. doi: 10.1016/j.celrep.2021.109293
[2] Data on file with Cleveland Clinic and MeCo Diagnostics Holdings, Inc.
[3] Quintela-Fandino, M. et al. (2024). Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-24-1518
Note: the prescribing information for the FDA-approved therapy may not include the associated biomarker, and the proposed intended use for the MeCo Score is subject to change.
*The MeCo Score (TM) assay is for Investigational Use Only
and is not cleared or approved by the Food and Drug Administration.
Copyright © 2024 MeCo Diagnostics Holdings, Inc. - All Rights Reserved.